Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 1.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.87 | 2.2 |
NAV | ₹128.35 | ₹101.59 |
Fund Started | 17 Jan 2008 | 25 Mar 1997 |
Fund Size | ₹6377.82 Cr | ₹1072.74 Cr |
Exit Load | Exit load of 1%, if redeemed within 90 days. | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 20.17% | 24.98% |
3 Year | 20.56% | 24.55% |
5 Year | 22.13% | 24.63% |
1 Year
3 Year
5 Year
Equity | 99.01% | 99.31% |
Cash | 0.99% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Infosys Ltd. | 3.81% |
ICICI Bank Ltd. | 3.55% |
NTPC Ltd. | 3.49% |
Ramkrishna Forgings Ltd. | 3.44% |
Mahindra & Mahindra Ltd. | 3.16% |
Tech Mahindra Ltd. | 3.10% |
Minda Corporation Ltd. | 2.95% |
Sun Pharmaceutical Industries Ltd. | 2.84% |
Welspun Corp Ltd. | 2.74% |
Reliance Industries Ltd. | 2.59% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Dhaval Joshi | Satish Ramanathan |
Start Date | 21 Nov 2022 | 01 Oct 2024 |
Name
Start Date
Description | The scheme seeks to generate consistent long-term capital appreciation by investing predominantly in equity and equity related securities by following value investing strategy i.e buying into stocks that are trading for less than their intrinsic value - stocks that the market is undervaluing. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 17 Jan 2008 | 25 Mar 1997 |
Description
Launch Date